Sang C. Ji
Seoul, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Population pharmacokinetic analysis of zastaprazan (JP-1366), a novel potassium-competitive acid blocker, in patients and healthy volunteers.
Journal: CPT: pharmacometrics & systems pharmacology
Published: March 19, 2024
Effect of SLC22A1 polymorphism on the pharmacokinetics of proguanil in Korean: A semi-physiologic population pharmacokinetic approach.
Journal: Clinical and translational science
Published: January 24, 2024
Evaluation of CYP2C19-Mediated Pharmacokinetic Drug Interaction of Tegoprazan, Compared with Vonoprazan or Esomeprazole.
Journal: Clinical pharmacokinetics
Published: February 15, 2023
Common ABCB1 SNP, C3435T could affect systemic exposure of dapagliflozin in healthy subject.
Journal: Translational and clinical pharmacology
Published: November 25, 2022
Randomised clinical trial: Safety, tolerability, pharmacodynamics and pharmacokinetics of zastaprazan (JP-1366), a novel potassium-competitive acid blocker, in healthy subjects.
Journal: Alimentary pharmacology & therapeutics
Published: August 17, 2022
Effects of vancomycin-induced gut microbiome alteration on the pharmacodynamics of metformin in healthy male subjects.
Journal: Clinical and translational science
Published: January 08, 2021
Assessment of Oral Vancomycin-Induced Alterations in Gut Bacterial Microbiota and Metabolome of Healthy Men.
Journal: Frontiers in cellular and infection microbiology
Published: November 14, 2020
The utility of CYP3A activity endogenous markers for evaluating drug-drug interaction between sildenafil and CYP3A inhibitors in healthy subjects.
Journal: Drug metabolism and pharmacokinetics
Published: September 30, 2020
Urinary metabolic markers reflect on hepatic, not intestinal, CYP3A activity in healthy subjects.
Journal: Drug metabolism and pharmacokinetics
Published: September 17, 2020
Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects.
Journal: Alimentary pharmacology & therapeutics
Published: June 04, 2020
Mechanism of Chronic Kidney Disease Progression and Novel Biomarkers: A Metabolomic Analysis of Experimental Glomerulonephritis.
Journal: Metabolites
Published: March 20, 2020
Author Correction: Ursodeoxycholic acid improves liver function via phenylalanine/tyrosine pathway and microbiome remodelling in patients with liver dysfunction.
Journal: Scientific reports
Published: November 14, 2019
Last Updated: 09/26/2026